Development of nebulized inhalation delivery for fusion-inhibitory lipopeptides to protect non-human primates against Nipah-Bangladesh infection.
Quick Facts
What This Study Found
A nebulized lipopeptide fusion inhibitor delivered to monkey lungs was safe and protected 2 of 5 monkeys from lethal Nipah virus infection, with all treated animals showing delayed disease and preserved immune cells.
Key Numbers
3 nebulized doses every 24 hours. Peptide deposited across multiple lung regions. 2 of 5 treated monkeys survived lethal NiV-Bangladesh challenge. No toxicity or adverse hematological/biochemical effects.
How They Did This
Aerosol delivery optimization using 3D respiratory model. Safety assessment in African green monkeys. Lethal Nipah-Bangladesh challenge study with peptide-treated vs. control monkeys.
Why This Research Matters
Nipah virus has no approved treatment or vaccine and kills up to 75% of those infected. An inhaled antiviral peptide that can be given quickly after exposure could fill a critical gap in pandemic preparedness.
What This Study Doesn't Tell Us
Only 2 of 5 monkeys fully protected. Small sample typical of BSL-4 primate studies. First-generation lipopeptide; next-generation versions being developed. Prophylactic dosing only, not post-exposure treatment.
Trust & Context
- Original Title:
- Development of nebulized inhalation delivery for fusion-inhibitory lipopeptides to protect non-human primates against Nipah-Bangladesh infection.
- Published In:
- Antiviral research, 235, 106095 (2025)
- Authors:
- Reynard, Olivier, Iampietro, Mathieu, Dumont, Claire, Le Guellec, Sandrine, Durand, Stephanie, Moroso, Marie, Brisebard, Elise, Dhondt, Kévin P, Pelissier, Rodolphe, Mathieu, Cyrille, Cabrera, Maria, Le Pennec, Deborah, Amurri, Lucia, Alabi, Christopher, Cardinaud, Sylvain, Porotto, Matteo, Moscona, Anne, Vecellio, Laurent, Horvat, Branka
- Database ID:
- RPEP-13251
Evidence Hierarchy
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13251APA
Reynard, Olivier; Iampietro, Mathieu; Dumont, Claire; Le Guellec, Sandrine; Durand, Stephanie; Moroso, Marie; Brisebard, Elise; Dhondt, Kévin P; Pelissier, Rodolphe; Mathieu, Cyrille; Cabrera, Maria; Le Pennec, Deborah; Amurri, Lucia; Alabi, Christopher; Cardinaud, Sylvain; Porotto, Matteo; Moscona, Anne; Vecellio, Laurent; Horvat, Branka. (2025). Development of nebulized inhalation delivery for fusion-inhibitory lipopeptides to protect non-human primates against Nipah-Bangladesh infection.. Antiviral research, 235, 106095. https://doi.org/10.1016/j.antiviral.2025.106095
MLA
Reynard, Olivier, et al. "Development of nebulized inhalation delivery for fusion-inhibitory lipopeptides to protect non-human primates against Nipah-Bangladesh infection.." Antiviral research, 2025. https://doi.org/10.1016/j.antiviral.2025.106095
RethinkPeptides
RethinkPeptides Research Database. "Development of nebulized inhalation delivery for fusion-inhi..." RPEP-13251. Retrieved from https://rethinkpeptides.com/research/reynard-2025-development-of-nebulized-inhalation
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.